Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$1,034.23 10.14 (0.99%) as of 4:30 Fri 7/5


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 108.27(B)
Last Volume: 418,302 Avg Vol: 758,271
52 Week Range: $692.45 - $1071.19
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 192,995 237,237 312,646 469,880
Total Sell Value $189,656,342 $231,855,596 $295,997,978 $406,115,303
Total People Sold 7 13 16 18
Total Sell Transactions 18 40 67 129
End Date 2024-04-07 2024-01-05 2023-07-07 2022-07-07

   
Records found: 2433
  Page 71 of 98  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Goldberg Murray A SVP Finance and Admin CFO Trea   •       –      –    2012-05-02 4 OE $21.92 $1,193,281 D/D 54,438 120,681     -
   Goldberg Murray A SVP Finance and Admin CFO Trea   •       –      –    2012-05-02 4 AS $134.64 $951,867 D/D (6,945) 80,166     -
   Schleifer Leonard S President & CEO   •       •      –    2012-05-01 4 AS $133.86 $13,482,553 D/D (100,000) 286,328     -
   Yancopoulos George EVP CSO President Regeneron Re   •       •      –    2012-05-01 4 AS $133.95 $4,471,669 D/D (33,165) 833,041     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2012-05-01 4 AS $134.52 $830,683 D/D (6,162) 10,000     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2012-04-30 4 D $138.31 $876,609 D/D (6,338) 16,162     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2012-04-30 4 OE $24.00 $300,000 D/D 12,500 22,500     -
   Baker Charles A Director   –       •      –    2012-04-19 4 AS $125.00 $1,613,750 D/D (12,910) 9,590     -
   Baker Charles A Director   –       •      –    2012-04-19 4 OE $18.80 $242,708 D/D 12,910 22,500     -
   Baker Charles A Director   –       •      –    2012-04-17 4 AS $125.00 $261,250 D/D (2,090) 9,590     -
   Baker Charles A Director   –       •      –    2012-04-17 4 OE $18.80 $39,292 D/D 2,090 11,680     -
   Vagelos P Roy Chairman of the Board   •       •      –    2012-03-30 4 GD $0.00 $0 I/I 1,852 165,909     -
   Yancopoulos George EVP CSO President Regeneron Re   •       •      –    2012-03-26 4 AS $120.21 $3,985,850 D/D (33,150) 866,206     -
   Goldstein Joseph L Director   –       •      –    2012-03-26 4 AS $120.00 $600,000 D/D (5,000) 0     -
   Goldstein Joseph L Director   –       •      –    2012-03-26 4 OE $18.61 $93,050 D/D 5,000 5,000     -
   Goldstein Joseph L Director   –       •      –    2012-03-15 4 AS $110.77 $1,128,966 D/D (10,000) 0     -
   Goldstein Joseph L Director   –       •      –    2012-03-15 4 OE $18.61 $186,100 D/D 10,000 5,000     -
   Shooter Eric M Director   –       •      –    2012-02-23 4 S $103.51 $2,070,632 I/I (20,000) 0     -
   Shooter Eric M Director   –       •      –    2012-02-23 4 A $0.00 $0 I/I 20,000 10,000     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2012-02-22 4 AS $94.71 $4,745,316 D/D (49,254) 15,144     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2012-02-21 4 D $100.32 $6,080,596 D/D (60,612) 64,398     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2012-02-21 4 OE $15.64 $1,989,055 D/D 109,866 72,662     -
   Mccorkle Douglas S VP Controller and Asst Treasur   •       –      –    2012-02-16 4 S $107.50 $575,448 D/D (5,353) 0     -
   Yancopoulos George EVP CSO President Regeneron Re   •       •      –    2012-02-15 4 D $109.29 $7,324,288 D/D (67,017) 899,356     -
   Yancopoulos George EVP CSO President Regeneron Re   •       •      –    2012-02-15 4 OE $8.50 $1,133,322 D/D 133,332 901,079     -
  2433 Records found
  Previous  70  71  72  73  74  75  76  77  78  79  Next   
  Page 71 of 98
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us